Propanc Biopharma, Inc. (PPCB): debt financing — Propanc Biopharma raises ~$180k via convertible notes and board loan; conversion at deep discounts

Propanc Biopharma, Inc.

$55k face convertible note issued at $50k (original issue discount) to GS Capital Partners; conversion price $5.00, drops to $2.50 if stock below $4 for 5 days.
$79.2k convertible note issued with 15% one-time interest; conversion at 65% of lowest trading price after default (35% discount).
$63k AUD loan from board member at 12% interest, due June 30, 2025; all proceeds for working capital.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Propanc Biopharma, Inc. incurred loan of aggregate principal amount of $63,188 AUD with one of our members of the Board of Directors at twelve percent (12%) per annum maturing June 30, 2025.

Instrument: loan
Principal: aggregate principal amount of $63,188 AUD
Counterparty: one of our members of the Board of Directors
Rate: twelve percent (12%) per annum
Maturity: June 30, 2025
Event: incurrence

Exact text from the filing

Effective April 13, 2025, the Company entered into and closed a loan agreement (the “Loan”) with one of our members of the Board of Directors (the “Board Member”), pursuant to which the Board Member loaned the Company an aggregate principal amount of $63,188 AUD.

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Propanc Biopharma, Inc. incurred convertible notes of aggregate principal amount of $55,000 with an investor at eight percent (8%) per annum maturing December 15, 2025.

Instrument: convertible notes
Principal: aggregate principal amount of $55,000
Counterparty: an investor
Rate: eight percent (8%) per annum
Maturity: December 15, 2025
Event: incurrence

Exact text from the filing

Effective April 15, 2025, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (“Purchase Agreement 1”) with an investor (“Investor 1”), pursuant to which Investor 1 agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $55,000 (“Note 1”), for a purchase price of $50,000.

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Propanc Biopharma, Inc. incurred convertible notes of aggregate principal amount of $79,200 with an investor at one-time interest charge of fifteen percent (15%) maturing January 30, 2026.

Instrument: convertible notes
Principal: aggregate principal amount of $79,200
Counterparty: an investor
Rate: one-time interest charge of fifteen percent (15%)
Maturity: January 30, 2026
Event: incurrence

Exact text from the filing

Effective March 31, 2025, the Company entered into and closed a securities purchase agreement (“Purchase Agreement 2”) with an investor (the “Investor 2”), pursuant to which Investor 2 agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $79,200 (“Note 2”), for a purchase price of $67,000.

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

Propanc Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-005511

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.